Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Common Equity: 2020-2025

Historic Common Equity for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $292.3 million.

  • GeneDx Holdings' Common Equity rose 42.91% to $292.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $292.3 million, marking a year-over-year increase of 42.91%. This contributed to the annual value of $245.2 million for FY2024, which is 7.56% up from last year.
  • As of Q3 2025, GeneDx Holdings' Common Equity stood at $292.3 million, which was up 5.46% from $277.1 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Common Equity peaked at $637.3 million during Q2 2022, and registered a low of -$566.5 million during Q2 2021.
  • Moreover, its 3-year median value for Common Equity was $254.3 million (2023), whereas its average is $253.2 million.
  • As far as peak fluctuations go, GeneDx Holdings' Common Equity skyrocketed by 7,720.41% in 2021, and later slumped by 54.70% in 2023.
  • GeneDx Holdings' Common Equity (Quarterly) stood at $388.1 million in 2021, then plummeted by 34.63% to $253.7 million in 2022, then dropped by 10.13% to $228.0 million in 2023, then increased by 7.56% to $245.2 million in 2024, then soared by 42.91% to $292.3 million in 2025.
  • Its last three reported values are $292.3 million in Q3 2025, $277.1 million for Q2 2025, and $257.4 million during Q1 2025.